An alternative view recognizes that endogenous GUCY2C ligands are suppressed early in transformation (again, by a mechanism yet to be defined), suggesting that a paracrine field of GUCY2C silencing is responsible for cGMP loss and tumor susceptibility. The gene discussed is GUCY2C; the disease is neoplasm.